CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Regencell Bioscience Holdings Limited  (NASDAQ: RGC)

Regencell Bioscience Holdings Limited's Working Capital Ratio

RGC's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth

Download as CSV



Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Working Capital Ratio deteriorated to 7.39 above company average Working Capital Ratio.

Within Legal Cannabis industry 2 other companies have achieved higher Working Capital Ratio than Regencell Bioscience Holdings Limited in fourth quarter 2025. While Working Capital Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 544.

Explain Working Capital Ratio
How much Current Assetss RGCīs has?
What are RGCīs Current Liabilities?


RGC Working Capital Ratio (Jun 30 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Jun 30 2023)
Q4
Y / Y Current Liabilities Change 9.36 % 9.36 % 9.36 % 9.36 % 5.04 %
Y / Y Current Assets Change -57.81 % -57.81 % -57.81 % -57.81 % -29.33 %
Working Capital Ratio MRQ 7.39 7.39 7.39 7.39 19.15
RGC's Total Ranking # 544 # # # #
Seq. Current Liabilities Change 0 % 0 % 0 % 9.36 % 0 %
Seq. Current Assets Change 0 % 0 % 0 % -57.81 % 0 %

New: More RGC's historic Working Capital Ratios >>


Working Capital Ratio fourth quarter 2025 Company Ranking
Within: No.
Legal Cannabis Industry # 3
Consumer Non Cyclical Sector # 8
Overall Market # 544


Working Capital Ratio Statistics
High Average Low
28.46 6.19 0.06
(Jun 30 2022)   (Jun 30 2021)




Financial Statements
Regencell Bioscience Holdings Limited's Current Liabilities $ 1 Millions Visit RGC's Balance sheet
Regencell Bioscience Holdings Limited's Current Assets $ 5 Millions Visit RGC's Balance sheet
Source of RGC's Sales Visit RGC's Sales by Geography


Cumulative Regencell Bioscience Holdings Limited's Working Capital Ratio

RGC's Working Capital Ratio for the trailling 12 Months

RGC Working Capital Ratio

 (Jun 30 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Jun 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth 9.36 % 8.32 % 7.25 % 6.16 % 5.04 %
Y / Y Current Assets TTM Growth -57.81 % -48.68 % -41.12 % -34.76 % -29.33 %
Working Capital Ratio TTM 7.39 10.13 13.01 16.01 19.15
Total Ranking TTM # 3348 # # # #
Seq. Current Liabilities TTM Growth 2.19 % 2.24 % 2.29 % 2.34 % 1.21 %
Seq. Current Assets TTM Growth -25.52 % -20.33 % -16.89 % -14.45 % -9.4 %

Working Capital ratio ranking by company, industry and sector >> Back to RGC Financial Strength Comparisons >> Go to Compare RGC Working Capital to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $0.66 millions, cumulative Working Capital Ratio decreased to 7.39 above the RGC average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Legal Cannabis industry 15 other companies have achieved higher Working Capital Ratio than Regencell Bioscience Holdings Limited. While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 3348.

Explain Working Capital Ratio
How much Current Assetss RGCīs has?
What are RGCīs Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Legal Cannabis Industry # 16
Consumer Non Cyclical Sector # 160
Within the Market # 3348


trailing twelve months Working Capital Ratio Statistics
High Average Low
28.46 5.89 0.06
(Jun 30 2022)   (Jun 30 2021)




Companies with similar Working Capital Ratio in the quarter ending Jun 30 2025, within Legal Cannabis Industry Working Capital RatioJun 30 2025 MRQ Current AssetsJun 30 2025 MRQ Current Liabilities
Mind Medicine mindmed Inc   9.95 $ 189.136  Millions$ 19.013  Millions
Regencell Bioscience Holdings Limited  7.39 $ 4.903  Millions$ 0.664  Millions
Niagen Bioscience Inc   3.88 $ 86.679  Millions$ 22.327  Millions
Canopy Growth Corporation  3.07 $ 232.373  Millions$ 75.581  Millions
Tilray Brands Inc   2.46 $ 688.626  Millions$ 280.303  Millions
Usana Health Sciences Inc   2.15 $ 261.866  Millions$ 121.625  Millions
Natural Alternatives International Inc  2.06 $ 59.276  Millions$ 28.804  Millions
Upexi Inc   1.74 $ 56.778  Millions$ 32.564  Millions
Fitlife Brands Inc   1.71 $ 22.177  Millions$ 12.968  Millions
Charlie s Holdings Inc   1.61 $ 5.846  Millions$ 3.635  Millions

Date modified: 2025-11-01T05:56:14+00:00



Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.